It has been shown that nano-activators treated DCs, through autophagy-dependent mechanisms, could increase antigen presentation and cross-presentation to T lymphocytes, increasing effector CD8+ T tumor infiltrating lymphocytes (TILs) (49). This evidence concerns the gene CD8A and neoplasm.